Abstract 2295P
Background
MET rearrangements are found in multiple cancers. Despite the availability of effective MET drugs there is no approved treatment for these tumors. We determined the prevalence of MET fusions, explored MET therapy in preclinical models and assessed efficacy of MET tyrosine kinase inhibitors (TKI) in a colorectal cancer (CRC) patient with MET fusion.
Methods
We analyzed the AACR project GENIE registry (release V13, 167,423 samples from 148,268 patients) for intergenic MET fusions. We also identified 2 CRC patients (Lenox Hill Hospital, New York, NY, and Renji Hospital Shanghai, China, respectively) by RNA-based NGS. MET expression was assessed by IHC. Sensitivity of SJ-GBM2 (CLIP::MET, glioblastoma), and H1993 and EBC1 (MET amplified lung cancer) cells to type 1 and type 2 MET TKIs were assessed.
Results
We identified 44/148,286 patients (0.03%) with an intergenic MET fusion; cancer types included brain (n=12; with 8 high-grade gliomas), NSCLC (n = 11 with 9 adenocarcinomas), gastrointestinal tract (n = 8; with 3 esophageal adenocarcinomas, 3 cholangiocarcinomas), etc. Recurrent fusion partners accounted for 18/44 (40.1%) cases and included 7 PTPRZ1, 5 ST7, 3 CTTNBP2, 2 CAPZA2 and 2 DOCK4. Two CRC patients with MET fusions (SYNRG2::MET, ZKSCAN1::MET) were found from routine NGS screening and both showed strong MET expression. Treatment with type 2 (cabozantinib) or type 1 (crizotinib, capmatinib, savolitinib) MET TKIs blocked growth of SJ-GBM2 cells with IC50 values of 0.3, 0.2, 0.1 and 0.04 μM, respectively, reflecting the sensitivity observed in H1993 and EBC1. MET TKIs blocked MET, AKT, ERK and S6 phosphorylation in SJ-GBM2 cells. These results were recapitulated with MET shRNAs. The CRC patient (SYNRG2::MET fusion) failed several lines of chemotherapy and was then treated with crizotinib, achieving a mixed response, with stable disease in lung metastases. Upon progression the patient was treated with capmatinib and a decrease in CEA from was observed after 3 weeks on therapy.
Conclusions
Our findings indicate MET fusions are widely distributed among tumor types and are sensitive to type 1 and type 2 MET TKIs. Clinical trials evaluating MET inhibitors for patients whose cancers are driven by MET fusions are ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
NIH.
Disclosure
M. Ladanyi: Financial Interests, Advisory Board: Merck, Bristol Myers Squibb, Takeda, Bayer, Lilly Oncology, Janssen, Paige.AI; Non-Financial Interests, Research Grant: Merus, Loxo Oncology, Elevation Oncology Inc., Hellsin. R. Somwar: Non-Financial Interests, Research Grant: Merus, Loxo Oncology, Elevation Oncology Inc., Hellsin. All other authors have declared no conflicts of interest.
Resources from the same session
2273P - Influence of body mass index (BMI) on the response to chemotherapy in patients with HER2+ breast cancer: Role of the leptin axis
Presenter: Marta González Rodríguez
Session: Poster session 08
2274P - Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study
Presenter: Christian Esposito
Session: Poster session 08
2275P - Circulating leptin and adiponectin levels in premenopausal women with and without breast cancer (BC) and a body mass index (BMI) ≥25 kg/m2
Presenter: Isabel Calvo
Session: Poster session 08
2276P - Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer
Presenter: Young Ju Jeong
Session: Poster session 08
2277P - A colorimetric biosensor to track Trop-2 status of tumor cells for diagnosis of breast cancer
Presenter: Tianyu Zeng
Session: Poster session 08
2278P - Endothelial cell heterogeneity defined by single-cell spatial transcriptomic analysis of breast cancers
Presenter: Krisztian Homicsko
Session: Poster session 08
2279P - Glucocorticoid receptor antagonism and beta adrenergic receptor inhibition: Implications in triple-negative breast cancer brain metastasis
Presenter: Andra Antohi
Session: Poster session 08
2280P - MiR-193a-3p: A pan-repressor of H2S synthesizing enzymes regulates tumorigenesis and immunosurveillance in breast cancer
Presenter: Alyaa Dawoud
Session: Poster session 08
2281P - Multi-omics evaluation of TFE3-fusions and potential association with immuno-metabolic vulnerabilities in alveolar soft part sarcoma (ASPS) and translocation-positive renal cell carcinoma (tRCC)
Presenter: Shuanzeng Wei
Session: Poster session 08
2282P - Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma
Presenter: Qin Jian Low
Session: Poster session 08